ANTXR1

Caris Life Sciences to Showcase Research Highlighting the Clinical Value of Comprehensive Molecular Profiling at the American Association for Cancer Research Annual Meeting

Retrieved on: 
星期四, 三月 28, 2024
Abstract, NCI, FOLFIRI, Prostate cancer, Immunotherapy, Adenocarcinoma, Colorectal cancer, PDLIM2, Physician, Patient, Lung, Biomarker, MSI, Breast, Cancer, AI, Doctor of Philosophy, Special session, MD, Lung cancer, Medicine, MBA, FOLFOX, AACR, PIM, MSS, Booth, POA, MRD, Future, Prognosis, SSP, ANTXR1, Vaccine

IRVING, Texas, March 28, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present 10 studies across eight tumor types at the 2024 American Association for Cancer Research (AACR) Annual Meeting on April 5-10, 2024, in San Diego, CA, at Booth Number 1105. Caris President, David Spetzler, MS, PhD, MBA, will lead an AACR Scientist ↔ Survivor Program® Special Session titled, "Very Early Cancer Detection Assays: The Future or Fantasy," on Tuesday, April 9, from 1:00 – 1:45 PM.

Key Points: 
  • Tissue-specific thresholds and microenvironment correlates of tumor mutation burden associated with immunotherapy benefit and prognosis in microsatellite stable cancers.
  • (Poster Number: 7037/4)
    Poster and abstract summaries highlighting the Caris research presented at AACR 2024 will be available onsite at Caris' Booth (# 1105).
  • The POA includes 91 cancer centers, academic institutions, research consortia and healthcare systems, including 43 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.
  • POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients.

Seneca Therapeutics Announces Publication of TEM8 Review Article “TEM8 in Oncogenesis” in Cells Journal

Retrieved on: 
星期三, 十一月 15, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Companion diagnostic, Clinical trial, ANTXR1, Neoplasm, Patient, Publication, Therapy, University, University of Miami, FDA, Medical device, Medical imaging, Cell

Seneca Therapeutics, Inc., announced today the publication of “TEM8 in Oncogenesis” in Cells.

Key Points: 
  • Seneca Therapeutics, Inc., announced today the publication of “TEM8 in Oncogenesis” in Cells.
  • The authors are Dr. Samuel Kareff and Dr. Aman Chauhan from Sylvester Cancer at University of Miami, Dr. Virginia Corbett from Mt.
  • Sinai Tisch Cancer Center and Dr. Paul Hallenbeck from Seneca Therapeutics.
  • “This review article provides an excellent update on both TEM8, ANTXR1 - the gene that encodes TEM8 - and SVV-001 which targets TEM8.

Seneca Therapeutics, Inc. Announces Issued U.S Patents for Tumor Endothelial Marker 8 (TEM8) Technology to Enable Better Patient Selection for SVV-001 Therapy

Retrieved on: 
星期二, 八月 24, 2021
Research, FDA, Genetics, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Cancer, ANTXR1, Genome, Memorial Sloan Kettering Cancer Center, Senecavirus, Method, SVV, Research, Patent, Therapy, United States patent law, 1836 U.S. Patent Office fire, Forward-looking statement, MSK, Patient, Invention, Pharmaceutical industry, Vaccine

TEM8 may enable pre-screening of solid tumors to determine if SVV-001 might be effective in that patient.

Key Points: 
  • TEM8 may enable pre-screening of solid tumors to determine if SVV-001 might be effective in that patient.
  • 11,096,972 B2 for Seneca valley virus (SVV) cellular receptor targeted oncotherapy, was issued today by the U.S. Patent Office.
  • Our exclusive license to these patents, with rights to sublicense, will help to maintain Seneca Therapeutics leadership in treating cancers using SVV.
  • Memorial Sloan Kettering (MSK) has intellectual property and associated interests related to Seneca by virtue of the licensing agreement between MSK and Seneca.